Isolation of Novel Fully Human Single-Domain Antibodies Targeting GUCY2C from a Heavy-Chain-Only Transgenic Mouse Platform
Technology in Cancer Research & Treatment · 2026-08 · 25
DOI: 10.1177/15330338261473054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 11.08.2026. Verfasst von Pingxia Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Antibody Discovery Department, SAFE Pharmaceutical Services Corp., Beijing, China. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Immunoglobulin Heavy Chains. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SAFE Pharmaceutical Services Corp.
Abstract (Originalsprache)
Introduction
Traditional natural single-domain antibodies(sdAbs) are primarily derived from camelids and sharks. However, the large size and slow reproduction of these species limit their widespread application in antibody development. In this study, we employed a fully human heavy-chain-only antibody mouse ( huNano mouse ) platform and a rapid, efficient preparation process to successfully develop fully human heavy-chain-only antibodies(HcAbs) targeting the tumor antigen guanylyl cyclase C (GC-C). These sdAbs provide high-quality candidate molecules for subsequent GC-C-based CAR-T therapy and bispecific antibody drug development.
Methods
Fully huNano mice were immunized with GC-C recombinant protein. SdAb sequences specifically binding to GC-C were selected via phage display technology and subsequently cloned into mammalian expression vectors for expression and purification. The binding activity, affinity, thermal stability, and monomeric dispersion of the antibodies were systematically evaluated using various methods, including ELISA, flow cytometry (FACS), biolayer interferometry (BLI), and size-exclusion chromatography (SEC-HPLC).
Results
Multiple sdAbs with specific recognition of GC-C were successfully obtained and exhibited strong binding affinities. After one-step purification, the monomeric purity of most antibodies exceeded 95%, with aggregate content below 5%. The nanobodies exhibited good thermal stability, with melting temperature (Tm) and aggregation onset temperature (Tagg) both falling within the range of 60–68 °C, demonstrating excellent drug development potential.
Conclusion
These results validate the capability of the huNano mouse platform to efficiently produce high-quality, fully human sdAbs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Antibody Discovery Department, SAFE Pharmaceutical Services Corp., Beijing, China.
- Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
- Gene Editing Department, Beijing Life-Biosciences Corp., Beijing, China.
ORCID-Profile: Pingxia Zhu
Förderung
- SAFE Pharmaceutical Services Corp
Zitieren
APA
Zhu, P., He, L., Du, X., Pang, P., Ji, Z., Yang, Y., Cao, F., & Wang, Q. (2026). Isolation of Novel Fully Human Single-Domain Antibodies Targeting GUCY2C from a Heavy-Chain-Only Transgenic Mouse Platform. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261473054
Vancouver
Zhu P, He L, Du X, Pang P, Ji Z, Yang Y, et al. Isolation of Novel Fully Human Single-Domain Antibodies Targeting GUCY2C from a Heavy-Chain-Only Transgenic Mouse Platform. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261473054
BibTeX
@article{Zhu2026,
author = {Zhu, Pingxia and He, Lei and Du, Xiaoming and Pang, Pengsha and Ji, Zhihua and Yang, Yanyu and Cao, Fengqi and Wang, Quanjun},
title = {Isolation of Novel Fully Human Single-Domain Antibodies Targeting GUCY2C from a Heavy-Chain-Only Transgenic Mouse Platform},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261473054}
}
EUVIMED